A breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals. Rather than producing medicines through batch-wise, step-by-step processes, CONTINUUS Pharmaceuticals offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals.
The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow "on-demand" manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs. CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT and Novartis on Continuous Manufacturing.
The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow "on-demand" manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs. CONTINUUS Pharmaceuticals is a spin-out company from a multi-year collaboration between MIT and Novartis on Continuous Manufacturing.
Services
CONTINUUS' mission is to produce high-quality drugs that can be delivered to patients more effectively and at a lower cost. In achieving this goal, we look to radically transform the pharmaceutical manufacturing industry, steering it away from outdated batch systems to state-of-the-art continuous processes.
Salvatore Mascia is the Founder & CEO of CONTINUUS Pharmaceuticals. He was the former Strategic Project Manager at the Novartis-MIT Center for Continuous Manufacturing, where he led the integration of the first end-to-end continuous manufacturing process for pharmaceuticals. At the end of the project, he was presented with the "Leadership Award" that recognized his leadership role at the Center.
CONTINUUS will offer clients significant advantages during commercial manufacturing. For companies that do not require in-house production, CONTINUUS's facilities will provide timely and cost-effective manufacturing services of high-quality pharmaceuticals. With their dial-up and dial-down capabilities, rapid changeover, and shortened lead times, our ICM lines will enable rapid responses to demand fluctuations, preventing costly stock outs.
ICM enables seamless end-to-end continuous manufacturing processes that incorporate API formation steps with final drug product formulation. By eliminating all the stops-and-starts that make current manufacturing processes time- and cost-inefficient, we are able to attain all the benefits associated with continuous manufacturing.
The unit operations that comprise our Integrated Continuous Manufacturing lines are novel, and provide advantages over existing conventional batch technologies. They permit reactions and formulation steps that are not possible in batch. The following unit operations are examples of process technologies we can implement for our clients:.
Reviews
Be the first to review Ind US Pharmaceuticals.
Write a Review
